Dr. Peter Forsberg | Myeloma Research News From the 2023 ASH Annual Meeting from Patient Empowerment Network on Vimeo.
Myeloma specialist Dr. Peter Forsberg reviews highlights from the 2023 American Society of Hematology (ASH) annual meeting. Dr. Forsberg shares what this promising news means for patients as well as advice for talking to your doctor about emerging therapies.
Dr. Peter Forsberg is associate professor of medicine at the University of Colorado School of Medicine and is a specialist in multiple myeloma. More about Dr. Forsberg.
See More from Evolve Myeloma
Dr. Peter Forsberg:
My name is Peter Forsberg. I’m an associate professor at the University of Colorado. I am a specialist in multiple myeloma and other plasma cell disorders. And I’m here at ASH, where it’s always the most exciting time of the year for those of us in the hematology and hematologic/oncology community, where we are getting all the breaking information around all kinds of diseases.
But a really exciting time in terms of new findings for myeloma and the other diseases we deal with.
I think it covers a really broad spectrum. That’s been one of the really exciting things about myeloma over the past decade really is that we’ve had developments in so many different directions in terms of new therapies, new options for patients who need later line treatments, new options improving early line therapy.
Certainly exciting to have a couple of very big studies that are being presented this year, two Phase III trials that look at four drug combinations in the newly diagnosed myeloma setting, which both show fantastic effectiveness. So, hopefully, really going to help expand that for patients with new myeloma to get really the best treatment out of the gate. And then, really maturing data around new immune therapies, both in the settings where they’re currently approved, which are sometimes later lines for myeloma patients. And then, more data on earlier lines for those therapies where they’re likely to be used in the very near future.
At this meeting and over the past year, and ASH is always a big summation of a lot of the research that’s going on at any given time, the breakthroughs that are happening in myeloma, the innovation that’s happening in myeloma is very impactful for patients. It’s giving us great, improved options for earlier line patients allowing them to live better, live longer, preserving quality of life and then, giving us diverse new options in relapsed myeloma where we’ve had good tools but the broadening of that toolbox is very exciting.
And it allows new and really effective options across all kinds of patient types. So, it’s really impactful across different settings.
Patients shouldn’t hesitate to ask what are the new and developing treatment options, to ask their physicians are there new treatment options for myeloma that might be a fit for me now or in the future? Don’t hesitate to think about what might come down the road, even if you’re in a steady place with your myeloma because things are changing quickly.
Our options now are different than they were six or 12 months ago and they’re going to be different six or 12 months from now.
So, don’t hesitate to ask what’s new, what’s coming, should I meet with a myeloma specialist to discuss some of those specific options and whether they’re a fit for me. So, don’t hesitate to be the squeaky wheel a little bit and say what might be out there for me now or in the future.